Sorafenib as first-line treatment for patients with primary hepatocellular carcinoma: an outcome evaluation
Objective To evaluate the clinical outcomes following first-line treatment with sorafenib in patients with primary hepatocellular carcinoma (HCC). Methods This retrospective cohort study enrolled patients with primary HCC that had been treated with sorafenib. Their data were collected from the hospi...
Main Authors: | Dung Thi Nguyen, Duong Hoang Nguyen, Van Thi Hong Nguyen |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-06-01
|
Series: | Journal of International Medical Research |
Online Access: | https://doi.org/10.1177/03000605231179928 |
Similar Items
-
Survival Outcome and Prognostic Factors Among Patients With Hepatocellular Carcinoma: A Hospital-Based Study
by: Dinh Cong Le, et al.
Published: (2023-06-01) -
Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma
by: Cuc Thi Dinh, et al.
Published: (2022-10-01) -
Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
by: Leonardo Gomes da Fonseca, et al.
Published: (2018-12-01) -
Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
by: Qiuping Chen, et al.
Published: (2024-01-01) -
Sorafenib for the treatment of advanced hepatocellular carcinoma
by: M Connock, et al.
Published: (2010-05-01)